Cargando…
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy
BACKGROUND: To investigate the third-year results of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV) in individualized treatment regimens based on the outcomes during 2 years. METHODS: One hundred seventy-two consecutive eyes of 163 prospective treatment-naïve patients with PCV w...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393615/ https://www.ncbi.nlm.nih.gov/pubmed/25881324 http://dx.doi.org/10.1186/s12886-015-0026-y |